Modalis Therapeutics Corporation [4883.T]
TOKYO, Mar 26 (Pulse News Wire) – Modalis Therapeutics Corporation (4883.T) announced that its board of directors approved the issuance of stock options to executives and employees. A total of 1,000 stock options will be granted to three directors, four employees, and 14 subsidiary employees, totaling 21 recipients.
Each option entitles the holder to purchase 100 common shares at an exercise price determined based on the average closing price of the company's common shares on the Tokyo Stock Exchange in February 2026, adjusted upward by 1.05%. The exercise period runs from March 27, 2028, to March 26, 2036.
The grant aims to incentivize long-term commitment and retain key talent without constituting a preferential issue requiring shareholder approval. The company retains the right to acquire unexercised options under certain conditions, such as termination of employment due to cause or resignation.
Additionally, the options cannot be transferred without board approval.
🟢 Confidence: High AI-translated content.